Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers I > Headlines for Insys Therapeutics Inc. > News item |
Insys Therapeutics operating loss widens to $9.15 million in September
By Caroline Salls
Pittsburgh, Oct. 31 – Insys Therapeutics, Inc. reported a $9.15 million loss from operations for September on $1.98 million in net revenue, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the District of Delaware.
In comparison, the company posted a $9.11 million loss from operations for August on $2.23 million in net revenue.
The net loss for September was $13.15 million, widening from a $200,535 August net loss.
In addition, Insys had $53.67 million in cash and cash equivalents as of Sept. 30, down from $55.12 million at the end of August.
The specialty pharmaceutical company is based in Phoenix. The company filed bankruptcy on June 10 under Chapter 11 case number 19-11292.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.